Medical Technology Stock Letter

BioInvest.com is the web home of the Medical Technology Stock Letter, an industry leading newsletter covering the biotech sector for almost thirty years.  Seeking information on FDA Approvals, Biotech Mergers & Acquisitions, Stock Picks, Long Investments and the occassional Short Sale?  Trying to stay on the cutting edge of scientific developments so you can stay ahead of the Markets? 

The Medical Technology Stock Letter is the source for Biotechnology news and investing advice.  Forget the pundits and the trends.  Here you find only experienced insight and the details that Wall Street doesn't want you to know.

Request a Free Issue then go to the Newsletter page to find out what's new at MTSL.

Subscribers, click here to log in or go directly to the Subscriber area.

Search BioInvest.com
Loading
Latest News from Yahoo! Finance

About Us

BioInvest.com is the web home of the Medical Technology Stock Letter and our top priority is to provide our Subscribers convenient access to the Letter and related information.  BioInvest.com aims to be a hub for biotechnology professionals, doctors and investors alike by providing a platform for the exchange of information about biotech, especially the drug development process.  Our hope is to make as much information as possible publicly available in a central location to give ordinary investors a bit of a head-start against Wall Street.  The big banks have mountains of information at their fingertips and will use the full weight of their enterprise to help make profitable investments, and the rest of us are left holding the bag.  BioInvest.com will help individual investors get ahead of the curve by informing you of market-moving events before they happen, by offering opinionated analysis and fostering a community discussion relating to important drug development news.

Medical Technology Stock Letter

The Medical Technology Stock Letter (MTSL) provides solid investment advice based on company and industry fundamentals. Our thirty years of experience in providing investment advice for this unique and volatile sector gives MTSL and YOU the edge. Our insistence on thorough research and knowledge of the forces moving the sector minimize your downside risk while maximizing your potential for capital growth. You won’t pay a fortune for MTSL either.

We’re making fresh company recommendations and providing more timely updates on breaking news than in the past. It’s not a change in investment philosophy—buying carefully selected biotech stocks and holding them long-term still promises the greatest return. But with more companies on our radar screen, a dynamic analyst team, and recommendations for long-term buying and short-selling stocks, there’s a lot to the new MTSL.

 Please click here to go to our Newsletter page and see more reasons to subscribe to MTSL.  Already convinced? Click here to subscribe now!